Catecholaminergic projections to tuberoinfundibular neurones of the paraventricular nucleus: III. Effects of adrenoceptor agonists and antagonists.
Stimulation of the ventral noradrenergic ascending bundle (VNAB) at low frequencies (0.5/5 Hz) excited the majority (37/46, 80%) of single paraventricular nucleus (PVN) tuberoinfundibular neurones, with high frequency (50 Hz) trains of stimuli reversing the direction of the response to inhibition for 7/16 (44%) of these excited cells. Iontophoretic application of noradrenaline, or the alpha 1-adrenoceptor agonist 1-phenylephrine, increased the spontaneous electrical activity of most of the cells tested (94% and 72%), whilst application of the alpha 1-antagonist, ergotamine reduced the spontaneous activity of 44% of the cells tested and prevented the excitation following VNAB stimulation for 84% of the cells examined. Application of the beta-adrenoceptor antagonist, propranolol, increased the spontaneous activity of 77% of cells and prevented the inhibitory PVN neuronal responses following high frequency VNAB stimulation of 94% of the cells, often reversing the response to excitation similar to that observed following low frequency VNAB stimulation. The alpha 2-adrenoceptor antagonist, tolazoline, was found to evoke mixed responses from the cells examined but a trend towards a suppression of spontaneous activity and potentiation of VNAB stimulation-evoked responses was observed. The alpha 2-adrenoceptor agonist, clonidine, elicited an initial excitation from the majority of cells tested, with most of the cells then exhibiting an inhibition, either with or without continued application. Excitatory responses following stimulation of the sciatic nerve were recorded from the majority of cells (82.5%) and ergotamine was able to suppress this response for all four cells so tested.(ABSTRACT TRUNCATED AT 250 WORDS)
Saphier
D
D
Department of Pharmacology and Therapeutics, Louisiana State University Medical Center, Shreveport 71130-3932.
Feldman
S
S
D000344:Afferent Pathways / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D003000:Clonidine / Q000494:pharmacology*; D004558:Electric Stimulation / Q000379:methods; D004878:Ergotamine / Q000494:pharmacology*; D007478:Iontophoresis; D008297:Male; D008473:Median Eminence / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D009638:Norepinephrine / Q000494:pharmacology*; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000502:physiology*; D010656:Phenylephrine / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000502:physiology*; D011943:Receptors, Adrenergic, beta / Q000187:drug effects / Q000502:physiology*; D012584:Sciatic Nerve / Q000502:physiology
D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D010656:Phenylephrine; D003000:Clonidine; D004878:Ergotamine; D009638:Norepinephrine